PTPI
Petros Pharmaceuticals, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$0.00
+3.36%Price chart
Oct 1Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30
Key dataOct 30, 2026
Open$0.00
From 52W high−91.30%
Volume64100.00
Market cap$84569.00
P/E (TTM)0.0x
P/S (TTM)—
Div yield—
Key dataOct 30, 2026
Open
$0.00
From 52W high
−91.30%
Volume
64100.00
Market cap
$84569.00
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
1.3x
P/E (TTM)
0.0x
RSI (14)
41.1
MomentumView details →
1D Return
+3.36%
YTD Return
−72.50%
SummaryUpdated Jun 1, 2026
Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) is a specialty pharmaceutical company founded in 2020 and headquartered in New York, New York. The company went public in December 2020 and focuses exclusively on developing and commercializing therapeutic solutions for men's health conditions. Since its inception, Petros has positioned itself as a niche player in the men's health pharmaceutical market, with particular emphasis on erectile dysfunction treatments and related urological conditions. The company has faced significant financial challenges in recent years, with declining revenues and substantial operating losses affecting its market position.
Similar companies
Latest newsMore news →
Petros Pharmaceuticals, Inc. announced the resignations of Executive Chairman Joshua N. Silverman, directors Bruce T. Bernstein and Wayne R. Walker, and Chief Accounting Officer Robert Weinstein, and the termination of President and Chief Commercial Officer Fady Boctor, all effective September 30, 2026.30d agoPetros Pharmaceuticals granted restricted shares to Chairman Joshua Silverman, director Bruce Bernstein, President and Chief Commercial Officer Fady Boctor, and director Wayne Walker on June 5, 2026.148d ago